WASHINGTON (dpa-AFX) – Ligand Pharmaceuticals Incorporated (LGND) has acquired Tolerance Therapeutics, Inc. for $20 million. Tolerance Therapeutics is a holding company, owned by the inventors of TZIELD, that is owed a royalty of less than 1% on worldwide net sales. TZIELD is the first disease-modifying therapy in type 1 diabetes.…Read More
Ligand Pharmaceuticals Acquires Royalty On TZIELD
